Hot Pursuit     06-Jul-23
Biocon gains as arm takes over Viatris' biosimilar biz in over 70 countries
Biocon rose 1.73% to Rs 261.15 after the company said that its subsidiary, Biocon Biologics has completed the integration of the acquired biosimilars business in over 70 countries in emerging markets, effective from 1 July 2023.

The company's arm took over commercialization of biosimilars business from Viatris in over 70 countries.

In February 2022, Biocon Biologics inked an agreement to acquire Viatris Inc's biosimilars business for $3.33 billion.

“Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries,” said the company.

The existing commercialized portfolio of biosimilars, including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, managed by Viatris in these markets, is now a part of Biocon Biologics' commercial organization.

Biocon stated in the press release, “We will work with existing and new partners to expand our footprint and strengthen our business presence in these countries. Our best-in-class R&D capabilities, high-quality manufacturing, supply chain excellence, and commercial and regulatory expertise will enable us to expand access to a diverse portfolio of biosimilars, meet patients' needs and be a trusted partner to patients and the healthcare community in these markets.”

Shreehas Tambe, CEO & managing director, Biocon Biologics said, “The successful integration of Viatris' biosimilars business to Biocon Biologics in over 70 countries is a significant milestone and marks the beginning of the transition process. Working closely with our partners, Biocon Biologics will now lead commercial operations in these markets and broaden access to patients with our differentiated portfolio of high quality biosimilars.”

Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

Biocon reported 31% rise in consolidated net profit to Rs 313 crore on a 57% increase in revenue from operations to Rs 3,774 crore in Q4 FY23 over Q4 FY22.

Previous News
  Indices trade with decent gains; realty shares rallied for 5th day
 ( Market Commentary - Mid-Session 17-May-24   12:40 )
  Biocon gains after receiving MHRA UK approval for Liraglutide injection
 ( Hot Pursuit - 01-Apr-24   10:34 )
  Biocon 's biologics subsidiary gets European Commission's nod for Aflibercept biosimilar
 ( Hot Pursuit - 21-Sep-23   09:24 )
  Biocon Ltd up for third straight session
 ( Hot Pursuit - 23-May-24   13:05 )
  Biocon AGM scheduled
 ( Corporate News - 17-May-24   13:47 )
  Biocon Ltd up for third consecutive session
 ( Hot Pursuit - 29-Sep-23   13:05 )
  Biocon Biologics receives UDFDA approval for Yesafili™
 ( Corporate News - 21-May-24   09:13 )
  Biocon
 ( Results - Analysis 24-May-23   10:32 )
  Biocon Ltd spurts 1.4%, rises for third straight session
 ( Hot Pursuit - 15-Jun-23   13:05 )
  Biocon Ltd rises for third straight session
 ( Hot Pursuit - 15-Feb-24   13:05 )
  Biocon allots NCDs aggregating Rs 1070 cr
 ( Corporate News - 21-Feb-23   18:58 )
Other Stories
  Basic materials stocks edge higher
  05-Nov-24   10:00
  Metal stocks edge higher
  05-Nov-24   10:00
  Auto stocks edge higher
  05-Nov-24   10:00
  Angel One client base climbs 58% YoY in Oct’24
  05-Nov-24   09:51
  KEC Intl Q2 PAT jumps 53% YoY to Rs 85 crore; order book at Rs 42,500 crore
  05-Nov-24   09:47
  Sharda Cropchem Ltd Spikes 7.83%
  05-Nov-24   09:30
  Prestige Estates Projects Ltd Slides 1.06%
  05-Nov-24   09:30
  Sandur Manganese to acquire additional 20% stake in ASPL
  05-Nov-24   08:45
  SPARC drops as Q2 net loss widens to Rs 107 crore
  04-Nov-24   17:01
  Tube Investments ends lower after Q2 PAT drops over 18% YoY even as revenue rises
  04-Nov-24   15:48
Back Top